Cargando…
Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
A growing appreciation of the overlapping neuroendocrine mechanisms controlling energy balance has highlighted combination therapies as a promising strategy to enhance sustained weight loss. Here, we investigated whether amylin- and glucagon-like-peptide-1 (GLP-1)-based combination therapies produce...
Autores principales: | Liberini, Claudia G., Koch-Laskowski, Kieran, Shaulson, Evan, McGrath, Lauren E., Lipsky, Rachele K., Lhamo, Rinzin, Ghidewon, Misgana, Ling, Tyler, Stein, Lauren M., Hayes, Matthew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560126/ https://www.ncbi.nlm.nih.gov/pubmed/31186439 http://dx.doi.org/10.1038/s41598-019-44591-8 |
Ejemplares similares
-
Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes
por: Wong, Gunther, et al.
Publicado: (2023) -
Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons
por: Boccia, Lavinia, et al.
Publicado: (2022) -
The satiating hormone amylin enhances neurogenesis in the area postrema of adult rats
por: Liberini, Claudia G., et al.
Publicado: (2016) -
GLP-1 physiology informs the pharmacotherapy of obesity
por: Drucker, Daniel J.
Publicado: (2021) -
Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin
por: Tufvesson-Alm, Maximilian, et al.
Publicado: (2023)